FDA Approves Unknown Drug — CHARTWELL RX

# FDA Approves Chartwell Rx Generic Drug Application Chartwell Rx has received FDA approval for its abbreviated new drug application (ANDA 207971), expanding the company's generic drug portfolio and positioning it to capture market share in an increasingly competitive generic pharmaceuticals sector. The approval enables Chartwell Rx to launch a generic alternative that could drive pricing competition and increase accessibility for patients while potentially offsetting revenue from branded competitors.